{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:57:54Z","timestamp":1772240274964,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>In patients with osteoporosis receiving antiresorptive agents (ARs), it has been widely practiced to withdraw ARs for several months before tooth extraction and during treatment if medication-related osteonecrosis of the jaw (MRONJ) develops. This study examined the effects of drug holidays on recovery from osteoclast suppression and the treatment outcomes. The relationship between the period of the drug holidays and treatment outcomes was examined retrospectively in 166 osteoporosis patients with MRONJ who received ARs. Histological examinations using hematoxylin and eosin staining and cathepsin K stains were performed to observe the recovery from osteoclast suppression in 43 patients in whom living bone was observed in the resection margins of the surgical specimens. Three-month AR drug holidays were not significantly correlated with the treatment outcomes of the 139 patients who underwent surgical treatment and the 27 who underwent conservative treatment. Of the 43 patients who underwent histological investigations, 16 had drug holidays from 7 to 678 days. Osteoclast suppression was observed in almost all patients, except in one without a drug holiday and one with a 261-day drug holiday. These findings suggest that AR drug holidays for approximately 3 months neither recover osteoclast suppression nor affect treatment outcomes.<\/jats:p>","DOI":"10.3390\/ijerph191710898","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T21:27:17Z","timestamp":1662067637000},"page":"10898","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ineffectiveness of Antiresorptive Agent Drug Holidays in Osteoporosis Patients for Treatment of Medication-Related Osteonecrosis of the Jaw: Consideration from Immunohistological Observation of Osteoclast Suppression and Treatment Outcomes"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-3933","authenticated-orcid":false,"given":"Keisuke","family":"Omori","sequence":"first","affiliation":[{"name":"Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2173-536X","authenticated-orcid":false,"given":"Mitsunobu","family":"Otsuru","sequence":"additional","affiliation":[{"name":"Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Hayashida","sequence":"additional","affiliation":[{"name":"Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Suyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomofumi","family":"Naruse","sequence":"additional","affiliation":[{"name":"Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakiko","family":"Soutome","sequence":"additional","affiliation":[{"name":"Department of Oral Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Umeda","sequence":"additional","affiliation":[{"name":"Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/01.bor.0000163448.51661.87","article-title":"The Use of Bisphosphonates in the Treatment of Osteoporosis","volume":"17","author":"Delmas","year":"2005","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic Acid versus Placebo in the Treatment of Skeletal Metastases in Patients with Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial\u2014The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab Compared with Zoledronic Acid for the Treatment of Bone Metastases in Patients with Advanced Breast Cancer: A Randomized, Double-Blind Study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab Compared with Zoledronic Acid on PFS in Multiple Myeloma: Exploratory Results of an International Phase 3 Study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw--2014 Update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive Agent-Related Osteonecrosis of the Jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw","volume":"35","author":"Yoneda","year":"2017","journal-title":"J. Bone Miner. Metab."},{"key":"ref_9","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-Related Osteonecrosis of the Jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.11005\/jbm.2021.28.4.279","article-title":"Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons","volume":"28","author":"Kim","year":"2021","journal-title":"J. Bone Metab."},{"key":"ref_11","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1007\/s00520-022-06940-8","article-title":"The Preventive Care of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Position Paper by Italian Experts for Dental Hygienists","volume":"30","author":"Mauceri","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral And Max-Illofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_13","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","article-title":"A Multicenter Retrospective Study of the Risk Factors Associated with Medication-Related Osteonecrosis of the Jaw after Tooth Extraction in Patients Receiving Oral Bisphosphonate Therapy: Can Primary Wound Closure and a Drug Holiday Really Prevent MRONJ?","volume":"28","author":"Hasegawa","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of Action of Bisphosphonates: Similarities and Differences and Their Potential Influence on Clinical Efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"ref_15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and Bisphosphonates: Different Mechanisms of Action and Effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"ref_16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ajoms.2021.12.010","article-title":"Duration of Drug Holiday of Oral Bisphosphonate and Osteoclast Morphology in Osteoporosis Patients with Medication-Related Osteonecrosis of the Jaw","volume":"34","author":"Morishita","year":"2022","journal-title":"J. Oral Maxillofac. Surg. Med. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Otsuru, M., Hayashida, S., Morishita, K., Murata, M., Soutome, S., Sasaki, M., Takagi, Y., Sumi, M., and Umeda, M. (2022). Retrospective Analysis of Treatment Outcomes of Maxillary Sinusitis Associated with Medication-Related Osteonecrosis of the Jaw. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19127430"},{"key":"ref_18","doi-asserted-by":"publisher","first-page":"11545","DOI":"10.1038\/s41598-022-15720-7","article-title":"Relationship between Drug Holiday of the Antiresorptive Agents and Surgical Outcome of Medication-Related Osteonecrosis of the Jaw in Osteoporosis Patients","volume":"12","author":"Morishita","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jds.2021.07.029","article-title":"A Preliminary Clinical Study of Segmental Mandibulectomy on Medication-Related Osteonecrosis of the Jaw","volume":"17","author":"Otsuru","year":"2022","journal-title":"J. Dent. Sci."},{"key":"ref_20","first-page":"33","article-title":"Bisphosphonate-Related Osteonecrosis of the Jaws: A Potential Alternative to Drug Holidays","volume":"61","author":"Damm","year":"2013","journal-title":"Gen. Dent."},{"key":"ref_21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12967-019-1819-1","article-title":"Osteoclastic Expression of Higher-Level Regulators NFATc1 and BCL6 in Medication-Related Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy: A Comparison with Osteoradionecrosis and Osteomyelitis","volume":"17","author":"Wehrhan","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","article-title":"Denosumab: Anti-RANKL Antibody","volume":"7","author":"Miller","year":"2009","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3892\/mco.2015.696","article-title":"Denosumab-Associated Osteonecrosis of the Jaw Affects Osteoclast Formation and Differentiation: Pathological Features of Two Cases","volume":"4","author":"Matsushita","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.4119","article-title":"A Drug Holiday Reduces the Frequency and Severity of Medication-Related Osteonecrosis of the Jaw in a Minipig Model","volume":"35","author":"Otto","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-019-0160-3","article-title":"Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): A retrospective clinical study","volume":"10","author":"Salgueiro","year":"2019","journal-title":"EPMA J."},{"key":"ref_26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00198-018-4746-8","article-title":"Medication-Related Osteonecrosis of the Jaw after Tooth Extraction in Cancer Patients: A Multicenter Retrospective Study","volume":"30","author":"Hasegawa","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_27","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00198-021-05995-3","article-title":"Denosumab-Related Osteonecrosis of the Jaw after Tooth Extraction and the Effects of a Short Drug Holiday in Cancer Patients: A Multicenter Retrospective Study","volume":"32","author":"Hasegawa","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5125\/jkaoms.2014.40.5.206","article-title":"Drug Holiday as a Prognostic Factor of Medication-Related Osteonecrosis of the Jaw","volume":"40","author":"Kim","year":"2014","journal-title":"J. Korean Assoc. Oral Maxillofac. Surg."},{"key":"ref_29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00784-017-2325-6","article-title":"Stage-Specific Therapeutic Strategies of Medication-Related Osteonecrosis of the Jaws: A Systematic Review and Meta-analysis of the Drug Suspension Protocol","volume":"22","author":"Ramaglia","year":"2018","journal-title":"Clin. Oral Investig."},{"key":"ref_30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00774-019-01035-7","article-title":"Drug Holiday Clinical Relevance Verification for Antiresorptive Agents in Medication-Related Osteonecrosis Cases of the Jaw","volume":"38","author":"Hayashida","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Otsuru, M., Soutome, S., Omori, K., Suyama, K., Morishita, K., Hayashida, S., Murata, M., Takagi, Y., Sasaki, M., and Sumi, M. (2022). Relationship between Drug Holidays of Antiresorptive Agents and Surgical Outcomes in Cancer Patients with Medication-Related Osteonecrosis of the Jaw. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19084624"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/17\/10898\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:21:39Z","timestamp":1760142099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/17\/10898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":31,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijerph191710898"],"URL":"https:\/\/doi.org\/10.3390\/ijerph191710898","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}